B-Cell Lymphoblastic Leukemia Monitoring for Minimal Residual Disease: Min Shi, M.D., Ph.D.
Min Shi, M.D., Ph.D., explains recent updates to the B-cell lymphoblastic leukemia minimal residual disease flow cytometry assay. This test is used to identify minimal residual disease in patients with a previously confirmed diagnosis of B-cell lymphoblas
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:45)
Could you just provide our listeners with a little bit of information about you and your background?
(01:00)
The laboratory recently made some updates to this testing for minimal residual disease. Can you just give us a brief overview of that assay?
(03:22)
So these patients go through these treatments, and at what point do they really need this testing, or when should it be considered by clinicians to perform it?
(05:18)
What brought the laboratory to flow cytometry for this MRD test for this particular disease state? Why did we not choose those other methods?
(09:44)
So hearing you talk about how this test is serving the entire patient population, how are these results for this minimal residual disease test used for patient care?